BROWSE

Related Scientist

Researcher

나노입자 연구단
나노입자 연구단
more info

Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging

Cited 10 time in webofscience Cited 0 time in scopus
365 Viewed 24 Downloaded
Title
Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging
Author(s)
Hwang, Eui Jin; Cha, Yongjun; Lee, A. Leum; Yun, Tae Jin; Kim, Tae Min; Park, Chul-Kee; Kim, Ji-Hoon; Sohn, Chul-Ho; Park, Sung-Hye; Kim, Il Han; Heo, Dae Seog; Lee, Se-Hoon; Seung Hong Choi
Publication Date
2013-05
Journal
JOURNAL OF NEURO-ONCOLOGY, v.112, no.3, pp.427 - 435
Publisher
SPRINGER
Abstract
Bevacizumab is a novel treatment for the recurrent high-grade gliomas (rHGG). However, only a subset of the patients shows response to the bevacizumab treatment and the response evaluation using conventional criteria is difficult. The purpose of our study was to evaluate the early response for rHGG treated with bevacizumab using volumetric analysis of diffusion-weighted imaging (DWI). Twenty-nine patients who received bevacizumab therapy for rHGG were included in our study. All patients received a conventional MRI scan with DWI before and after the initial bevacizumab dose. For each MRI, we measured the total volume of the T2 hyperintense lesion (HT2) of the rHGG, the volume of foci with a lower ADC value than that of the normal cortex (LADC), and the proportion of LADC to HT2 (LADC/HT2). The Changes in the HT2, LADC and LADC/HT2 after bevacizumab treatment were also determined. Thereafter, those volumetric data were compared to the progression free survival (PFS). After the analyses, we found a significant negative correlation between the PFS and the LADC for the post-bevacizumab ADC maps (r = -0.413, P = 0.026). The patients with an LADC of\2.5 cm3 showed a longer PFS than those with an LADC of C2.5 cm3 (median = 135 vs. 91 days, P = 0.002) on the post-bevacizumab ADC maps. A multiple linear regression analysis revealed that only the postbevacizumab LADC was a significant predictor of the PFS (P = 0.026). In conclusion, the post-bevacizumab LADC can be used for an early response evaluation and can predict the PFS for rHGG patients treated with bevacizumab.
URI
https://pr.ibs.re.kr/handle/8788114/1347
ISSN
0167-594X
Appears in Collections:
Center for Nanoparticle Research(나노입자 연구단) > Journal Papers (저널논문)
Files in This Item:
28. Early response evaluation for recurrent high grade gliomas treated with bevacizumab a volumetric analysis using diffusion-weighted imaging.pdfDownload

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse